Drug deals are back and Mylan Inc. wants in.
Valeant Pharmaceuticals International Inc.’s deal-fueled quest to become a $150 billion company has some investors doubting the strategy as it loads up on debt.
With drugmakers pursuing deals like never before, Shire Plc’s best defense against becoming a target may be to go on the hunt itself.
Actavis Plc’s purchase of Forest Laboratories Inc. accelerates a pharmaceutical merger wave that stands to engulf even more drugmakers.
Impax Laboratories Inc. failed to win U.S. approval for a new version of an extended-release drug used to relieve spasms in patients with Parkinson’s disease.
Impax Laboratories Inc. declined the most in more than two months after the company failed to win U.S. approval for an extended-release formulation of a Parkinson’s disease drug used to relieve spasms in patients.
"It was a shocker they allowed their wholesalers to keep nine months of inventory in the channel."
- David Amsellem on Dec 16, 2014